Immunoreactivity of CD99 in non-Hodgkin's lymphoma: Unexpected frequent expression in ALK-positive anaplastic large cell lymphoma

Journal of Korean Medical Science

Volumn 20, Issue 6, 2005, Pages 952-956

  Chang, Ohk Sung ^a   Ko, Young H ^a   Park, Sanghui ^a   Kim, Kihyun ^a   Kim, Wonseog ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

CD99 protein, human; Lymphoma, Large Cell, Ki 1; Lymphoma, Non Hodgkin

Indexed keywords

EID: 31544444424     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2005.20.6.952     Document Type: Article

References (26)

1. Hahn JH, Kim MK, Choi EY, Kim SH, Sohn HW, Ham DI, Chung DH, Kim TJ, Lee WJ, Park CK, Ree HJ, Park SH. CD99 (MIC2) regulates the LFA-1/ICAM-1-mediated adhesion of lymphocytes, and its gene encodes both positive and negative regulators of cellular adhesion. J Immunol 1997; 159: 2250-8.
2. Waclavicek M, Majdic O, Stulnig T, Berger M, Sunder-Plassmann R, Zlabinger GJ, Baumruker T, Stockl J, Ebner C, Knapp W, Pickl WF. CD99 engagement on human peripheral blood T cells results in TCR/CD3-dependent cellular activation and allows for Th1-restricted cytokine production. J Immunol 1998; 161: 4671-8.
3. Hamilton G, Fellinger EJ, Schratter I, Fritsch A. Characterization of a human endocrine tissue and tumor-associated Ewing's sarcoma antigen. Cancer Res 1988; 48: 6127-31.
4. Weidner N, Tjoe J. Immunohistochemical profile of monoclonal antibody O13: antibody that recognizes glycoprotein p30/32MIC2 and is useful in diagnosing Ewing's sarcoma and peripheral neuroepithelioma. Am J Surg Pathol 1994; 18: 486-94.
5. Ramani P, Rampling D, Link M. Immunocytochemical study of 12E7 in small round-cell tumours of childhood: an assessment of its sensitivity and specificity. Histopathology 1993; 23: 557-61.
6. Pelosi G, Fraggetta F, Sonzogni A, Fazio N, Cavallon A, Viale G. CD99 immunoreactivity in gastrointestinal and pulmonary neuroendocrine tumours. Virchows Arch 2000; 437: 270-4.
7. Gordon MD, Corless C, Renshaw AA, Beckstead J. CD99, keratin, and vimentin staining of sex cord-stromal tumors, normal ovary, and testis. Mod Pathol 1998; 11: 769-73.
8. Granter SR, Renshaw AA, Fletcher CD, Bhan AK, Rosenberg AE. CD99 reactivity in mesenchymal chondrosarcoma. Hum Pathol 1996; 27: 1273-6.
9. Jung KC, Park WS, Bae YM, Hahn JH, Hahn K, Lee H, Lee HW, Koo HJ, Shin HJ, Shin HS, Park YE, Park SH. Immunoreactivity of CD99 in stomach cancer. J Korean Med Sci 2002; 17: 483-9.
10. Yoo SH, Han J, Kim TJ, Chung DH. Expression of CD99 in pleomorphic carcinomas of the lung. J Korean Med Sci 2005; 20: 50-5.
11. Robertson PB, Neiman RS, Worapongpaiboon S, John K, Orazi A. 013 (CD99) positive in hematologic proliferations correlates with TdT positivity. Mod Pathol 1997; 10: 277-82.
12. Zhang PJ, Barcos M, Stewart CC, Block AW, Sait S, Brooks JJ. Immunoreactivity of MIC2 (CD99) in acute myelogenous leukemia and related diseases. Mod Pathol 2000; 13: 452-8.
13. Riopel M, Dickman PS, Link MP, Perlman EJ. MIC2 analysis in pediatric lymphomas and leukemias. Hum Pathol 1994; 25; 396-9.
14. Vartanian RK, Sudilovsky D, Weidner N. Immunostaining of monoclonal antibody 013 [anti-MIC2 gene product (CD99)] in lymphomas; impact of heat-induced epitope retrieval. Appl Immunohistochem 1996; 4: 43-55.
15. World Health Organization Classification of Tumors. Pathology & Genetics. Tumors of Hematopoietic and Lymphoid Tissues. Jaffe ES, Harris NL, Stein H, and Vardiman J eds. IARC Press, Lyon, 2001.
16. Dworzak MN, Fritsch G, Buchinger P, Fleischer C, Printz D, Zellner A, Schollhammer A, Steiner G, Ambros PF, Gadner H. Flow cytometric assessment of human MIC2 expression in bone marrow, thymus, and peripheral blood. Blood 1994; 83: 415-25.
17. Dworzak MN, Fritsch G, Fleischer C, Printz D, Froschl G, Buchinger P, Mann G, Gadner H. CD99 (MIC2) expression in paediatric B-lineage leukaemia/lymphoma reflects maturation-associated patterns of normal B-lymphopoiesis. Br J Haematol 1999; 105: 690-5.
18. Stein H, Herbst H, Anagnostopoulos I, Niedobitek G, Dallenbach F, Kratzsch HC. The nature of Hodgkin and Reed-Sternberg cells, their association with EBV, and their relationship to anaplastic large-cell lymphoma. Ann Oncol 1991; Suppl 2: 33-8.
19. Leoncini L, Del Vecchio MT, Kraft R, Megha T, Barbini P, Cevenini G, Poggi S, Pileri S, Tosi P, Cottier H. Hodgkin 's disease and CD30-positive anaplastic large cell lymphomas-a continuous spectrum of malignant disorders. A quantitative morphometric and immunohistologic study. Am J Pathol 1990; 137: 1047-57.
20. Lee IS, Shin YK, Chung DH, Park SH. LMP1-induced down-regulation of CD99 molecules in Hodgkin and Reed-Sternberg cells. Leuk Lymphoma 2001; 42: 587-94.
21. Bargou RC, Leng C, Krappmann D, Emmerich F, Mapara MY, Bommert K, Royer HD, Scheidereit C, Dorken B. High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 1996; 87: 4340-7.
22. Horie R, Watanabe M, Ishida T, Koiwa T, Aizawa S, Itoh K, Higashihara M, Kadin ME, Watanabe T. The NPM-ALK oncoprotein abrogates CD30 signaling and constitutive NF-kappaB activation in anaplastic large cell lymphoma. Cancer Cell 2004; 5: 353-64.
23. Jung KC, Kim NH, Park WS, Park SH, Bae Y. The CD99 signal enhances Fas-mediated apoptosis in the human leukemic cell line, Jurkat. FEBS Lett 2003; 554: 478-84.
24. Cerisano V, Aalto Y, Perdichizzi S, Bernard G, Manara MC, Benini S, Cenacchi G, Preda P, Lattanzi G, Nagy B, Knuutila S, Colombo MP, Bernard A, Picci P, Scotlandi K. Molecular mechanisms of CD99-induced caspase-independent cell death and cell-cell adhesion in Ewing's sarcoma cells: actin and zyxin as key intracellular mediators. Oncogene 2004; 23: 5664-74.
25. ten Berge RL, Meijer CJ, Dukers DF, Kummer JA, Bladergroen BA, Vos W, Hack CE, Ossenkoppele GJ, Oudejans JJ. Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma. Blood 2002; 99: 4540-6.
26. Rassidakis GZ, Sarris AH, Herling M, Ford RJ, Cabanillas F, McDonnell TJ, Medeiros LJ. Differential expression of BCL-2 family proteins in ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null-cell lineage. Am J Pathol 2001; 159: 527-35.